RANI (Rani Therapeutics Holdings) Stock Based Compensation: $9.96 Mil (TTM As of Mar. 2026)


RANI Rani Therapeutics Holdings Inc RANI
32 GF Score
Price $0.78
! 3 Warning Signs
View Full Analysis

What is Rani Therapeutics Holdings Stock Based Compensation?

Rani Therapeutics Holdings RANI +0.38% 32 Stock Based Compensation is $9.96 Mil as of Mar. 2026. GuruFocus rates RANI with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

Rani Therapeutics Holdings's Stock Based Compensation for the three months ended in Mar. 2026 was $2.08 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $9.96 Mil.

Rani Therapeutics Holdings Stock Based Compensation Related Terms

Rani Therapeutics Holdings Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Rani Therapeutics Holdings's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rani Therapeutics Holdings Stock Based Compensation Chart

Rani Therapeutics Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial 22.60 15.78 19.01 16.03 11.80

Rani Therapeutics Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.93 3.29 2.34 2.24 2.08
RANI
32GF Score
Rani Therapeutics Holdings Inc RANI
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rani Therapeutics Holdings Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.96 Mil.

What does a Stock Based Compensation of $9.96 Mil mean?
Rani Therapeutics Holdings (RANI) has a Stock Based Compensation of $9.96 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Rani Therapeutics Holdings and its competitors.
Is Rani Therapeutics Holdings' Stock Based Compensation too high?
Rani Therapeutics Holdings' current Stock Based Compensation is $9.96 Mil. Overall, Rani Therapeutics Holdings has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Rani Therapeutics Holdings' Stock Based Compensation compare to IBIO and RNTX?
Rani Therapeutics Holdings' Stock Based Compensation of $9.96 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Rani Therapeutics Holdings and its competitors. Rani Therapeutics Holdings's current Stock Based Compensation is $9.96 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rani Therapeutics Holdings stock overvalued right now?
Rani Therapeutics Holdings (RANI) has a current Stock Based Compensation of $9.96 Mil. The current Stock Based Compensation is $9.96 Mil. Rani Therapeutics Holdings' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Rani Therapeutics Holdings (RANI), the current Stock Based Compensation is $9.96 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rani Therapeutics Holdings Business Description

Address 2051 Ringwood Avenue, San Jose, CA, USA, 95131
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
32GF Score

Get the complete analysis for RANI

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.78
Price